B+
Bull case
0%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
SLDB
Solid BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
1%
Probability
Target price
$8.60
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+55.2
Score
AI commentary
Primary-source evidence supports a cautious monitoring setup rather than a high-conviction bullish call: Solid has real 2026 operating milestones and better runway after the March financing, but the stock still depends heavily on near-term Phase 3 execution and regulatory clarity around SGT-003 in a Duchenne field that now has clearer direct comparators. Deterministic priors are negative and catalyst density is still light, so sentiment stays restrained despite multiple upcoming checkpoints.
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-04-30eventFirst Phase 3 IMPACT DUCHENNE dosingHigh impact
Management said it anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026, which is the clearest near-term operating checkpoint for SGT-003 execution after FDA alignment on study design [#PR-2026-03-19] [#PR-2026-02-09].
2026-06-30eventFDA follow-up on accelerated approval pathwayHigh impact
Solid said additional FDA meetings are planned in H1 2026 to seek guidance on a potential accelerated approval pathway for SGT-003; constructive feedback would matter more than generic trial progress because it could shape the registrational path [#PR-2026-03-19] [#PR-2026-02-09].
2026-06-30catalystRunway extension lowers immediate financing pressureHigh impact
March 2026 business updates and financing materials indicate $187.9 million of cash at December 31, 2025, a completed $240 million private placement, and expected runway into H1 2028, reducing near-term financing stress but not eliminating later dilution risk as clinical spend ramps [#PR-2026-03-19] [#PR-2026-03-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology